Shared idiotype expression by chronic lymphocytic leukemia and B-cell
lymphoma
M Chatterjee, M Barcos, T Han, XL Liu, Z Bernstein and KA Foon
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263.
Antiidiotype (Id) antibodies identify unique determinants within the
surface immunoglobulin (Ig) that are present on B-cell tumors. Anti-Ids
have been used for diagnosis and therapy of B-cell lymphoma and leukemia. A
panel of 29 anti-Id monoclonal antibodies (MoAbs) that recognize shared
idiotypes (SIds) on B-cell lymphomas was tested for reactivity with both
B-cell leukemias and lymphomas. Ten of 40 (25%) cases of chronic
lymphocytic leukemia (CLL) reacted with at least one of the 29 anti-SId
MoAbs. Three cases reacted with more than one anti- SId MoAb, but there was
no repetitive pattern of a single anti-SId MoAb reacting with a large
proportion of CLL cases. In contrast, for B-cell lymphoma, in which 11 of
31 (36%) cases reacted, one anti-SId (B4-1) reacted with five of the
positive cases; all were diffuse histology. Restricted anti-SId reactivity
may lead to important insights into the etiology of certain B-cell
lymphomas. In addition, these anti-SIds may obviate the need to develop
"tailor-made" antibodies for individual patients.
Volume 76,
Issue 9,
pp. 1825-1829,
11/01/1990
Copyright © 1990 by The American Society of Hematology
